Q4 Earnings Form 10-K. Earnings Release 242.8 KB. Podcast. Financial Workbook 284.6 KB. Financial Workbook 164.7 KB. Earnings Presentation 376.5 KB. Q3 Earnings Form 10-Q. Earnings Release 147.3 KB. Podcast. Financial Workbook 160.1 KB. Financial Workbook 281.2 KB. Earnings Presentation 301.9 KB.

Feb 6, 2024 · New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.

Jan 14, 2025 · 2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance. Q4 2024 revenue is expected to be approximately $13.5 billion, approximately $400 million below the low end of recently issued financial guidance . The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth ...

3 days ago · Eli Lilly and Company issued Q3 2024 earnings on October 30, 2024, reporting an EPS of $1.18, which missed analysts' consensus estimates of $1.52 by $0.34. Quarterly revenue rose 20.4% year-over-year to $11.44 billion, below analysts' expectations of $12.09 billion.

Jan 15, 2025 · Eli Lilly and Company ’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers....

Jan 14, 2025 · Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion. The company’s expected 2024...

Feb 6, 2024 · LLY - Free Report) reported fourth-quarter 2023 adjusted earnings per share (“EPS”) of $2.49, which beat the Zacks Consensus Estimate of $2.46 per share. Earnings rose 19% year over year....

Feb 6, 2024 · Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher …

Feb 6, 2024 · Eli Lilly (LLY 2.45%) Q4 2023 Earnings Call Feb 06, 2024, 10:00 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator

Feb 6, 2024 · Eli Lilly and Company (NYSE: LLY) on Tuesday reported double-digit growth in revenues and adjusted earnings for the fourth quarter of 2023. The Indianapolis-based pharmaceutical company said its revenues increased 28% year-over-year to $9.35 billion in the December quarter, aided by strong growth across the key operating divisions.